Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies

NCT ID: NCT00886522

Last Updated: 2021-03-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2013-05-31

Brief Summary

The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by high risk hematological malignancies after intrabone infusion of cord blood.

Detailed Description

For many hematological malignancies, hemopoietic stem cell (HSC) transplant is the only possible treatment. The source of HSC is often bone marrow (BM) or, in the past 10 years, peripheral blood cell (PBSC) mobilized by granulocyte growth factor. Transplant needs a HLA compatible (related or unrelated) donor. Around 10-30% of patients with indication for allogeneic HSC transplant are not able to undergo the procedure because of the lack of a HLA compatible donor. Cord blood (CB) cells represent another possible source, which needs a lower degree of HLA compatibility, this type of transplant, however, offers a lower number of HSC. For this reason, adult patients, until now, could not use this source, because of the not suitable number of cell per kg, of recipient body weight. Recently, in experimental animal models it was observed that intrabone HSC transplant allows, in the recipient, engraftment of donor hemopoiesis by using a 1Log (10-1) lower number of cells compared to the intravenous way (Yahata 2003, Castello 2004). Safety and feasibility of intrabone infusion was verified by two clinical studies on humans: the first was conducted by Ringden O. et al. in 18 patients without any evidence of collateral effects and with complete engraftment of donor hemopoiesis with BM as a source of HSC (Hagglund 1998); the second one was conducted by Frassoni et al. (Frassoni 2008) with CB as the source of HSC.

The aim of this study is to evaluate the intrabone infusion instead of the intravenous one, for the HSC transplant from CB in patients with haematological malignancies when it is not possible to find a HLA matched donor.

We will perform:

• evaluation of the engraftment kinetics;
• evaluation of the chimerism degree at 30, 60, 100 days, 6 months and 1 year after transplant;
• studies on immunological reconstitution and the role of the NK compartment.

Conditions

Hematological Malignancies

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intrabone cord blood infusion

All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.

Group Type: EXPERIMENTAL

Intrabone cord blood infusion

Intervention Type: PROCEDURE

Myeloablative conditioning regimen (MAC):

i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg

Reduced intensity conditioning regimen (RIC):

Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg

GVHD prophylaxis:

Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27

Interventions

Intrabone cord blood infusion

Myeloablative conditioning regimen (MAC):

i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg

Reduced intensity conditioning regimen (RIC):

Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg

GVHD prophylaxis:

Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Age between 18 and 65 years.
• Patients affected by hematological malignancies without a HLA identical sibling donor or unrelated donor.
• Informed consent.

Exclusion Criteria

• Patients with ECOG < 2.
• Patients with blood creatine > 2 mg/dl or with transaminase or cholestase index > 5 times compared to normality upper limits.
• Patients with Cardiac Fraction Ejection < 40%.
• Patients with DLCO < 60% or Diffusing Lung Capacity of carbon monoxide attesting a severe pulmonary insufficiency.
• Patients with peripheral blast cell count over 10%.
• Second neoplasia diagnosed no more than 2 years before.
• Patients with active or suspected infection by fungi for which a therapeutic treatment is ongoing.
• HIV positive patients.
• HCV-RNA and HBV-RNA positive patients (it is possible to enrol them after discussion with the Principal Investigator).
• Pregnant or lactating women.
• Severe mental diseases.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role: lead

Responsible Party

Francesca Bonifazi, MD

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Francesca Bonifazi, MD

Role: PRINCIPAL_INVESTIGATOR

S. Orsola-Malpighi University Hospital

Locations

Hematology Institute "L. and A. Seràgnoli", S. Orsola-Malpighi University Hospital

Bologna, , Italy

Countries

Italy

References

Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9. doi: 10.1016/j.bbmt.2006.08.041.

Reference Type: BACKGROUND

PMID: 17222756 (View on PubMed)

Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood. 2001 May 15;97(10):2957-61. doi: 10.1182/blood.v97.10.2957.

Reference Type: BACKGROUND

PMID: 11342417 (View on PubMed)

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003 Sep 1;102(5):1915-9. doi: 10.1182/blood-2002-11-3337. Epub 2003 May 8.

Reference Type: BACKGROUND

PMID: 12738676 (View on PubMed)

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005 Feb 1;105(3):1343-7. doi: 10.1182/blood-2004-07-2717. Epub 2004 Oct 5.

Reference Type: BACKGROUND

PMID: 15466923 (View on PubMed)

Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, Baxter-Lowe LA, Schwartz J, Qualter E, Hawks R, Wolownik K, Foley S, Militano O, Leclere J, Cheung YK, Cairo MS. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant. 2007 Oct;40(7):621-31. doi: 10.1038/sj.bmt.1705785. Epub 2007 Jul 30.

Reference Type: BACKGROUND

PMID: 17660841 (View on PubMed)

Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007 Oct 15;110(8):3064-70. doi: 10.1182/blood-2007-04-067215. Epub 2007 Jun 14.

Reference Type: BACKGROUND

PMID: 17569820 (View on PubMed)

Cornetta K, Laughlin M, Carter S, Wall D, Weinthal J, Delaney C, Wagner J, Sweetman R, McCarthy P, Chao N. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant. 2005 Feb;11(2):149-60. doi: 10.1016/j.bbmt.2004.11.020.

Reference Type: BACKGROUND

PMID: 15682076 (View on PubMed)

Cohen Y, Nagler A. Umbilical cord blood transplantation--how, when and for whom? Blood Rev. 2004 Sep;18(3):167-79. doi: 10.1016/S0268-960X(03)00064-X.

Reference Type: BACKGROUND

PMID: 15183901 (View on PubMed)

De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri SB, Carella A, Apperley J, Gratwohl A, Laporte JP. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood. 1997 Nov 15;90(10):3853-7.

Reference Type: BACKGROUND

PMID: 9354651 (View on PubMed)

Dick JE and Lapidot T. Stem cells take a shortcut to the bone marrow. Blood 2003(101):2901-2902.

Reference Type: BACKGROUND

Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JE. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007 Jun 9;369(9577):1947-54. doi: 10.1016/S0140-6736(07)60915-5.

Reference Type: BACKGROUND

PMID: 17560447 (View on PubMed)

Fanning LR, Hegerfeldt Y, Tary-Lehmann M, Lesniewski M, Maciejewski J, Weitzel RP, Kozik M, Finney M, Lazarus HM, Paul P, Ratajczak MZ, Meyerson HJ, Laughlin MJ. Allogeneic transplantation of multiple umbilical cord blood units in adults: role of pretransplant-mixed lymphocyte reaction to predict host-vs-graft rejection. Leukemia. 2008 Sep;22(9):1786-90. doi: 10.1038/leu.2008.55. Epub 2008 Mar 20. No abstract available.

Reference Type: BACKGROUND

PMID: 18354493 (View on PubMed)

Frassoni F, Gualandi F, Podestà M et al. Direct intra-bone injection of unrelated cord blood cells overcomes the problem of delayed/failure to engraft and improves the feasibility of haematopoietic transplant in adult patients. Bone Marrow Transp 41(81):21, 2008.

Reference Type: BACKGROUND

Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989 Oct 26;321(17):1174-8. doi: 10.1056/NEJM198910263211707. No abstract available.

Reference Type: BACKGROUND

PMID: 2571931 (View on PubMed)

Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan KW, Takahashi TA, Ortega J, Filipovich A, Locatelli F, Asano S, Fagioli F, Vowels M, Sirvent A, Laporte JP, Tiedemann K, Amadori S, Abecassis M, Bordigoni P, Diez B, Shaw PJ, Vora A, Caniglia M, Garnier F, Ionescu I, Garcia J, Koegler G, Rebulla P, Chevret S; Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004 Apr;32(4):397-407. doi: 10.1016/j.exphem.2004.01.002.

Reference Type: BACKGROUND

PMID: 15050751 (View on PubMed)

Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang C. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997 Aug 7;337(6):373-81. doi: 10.1056/NEJM199708073370602.

Reference Type: BACKGROUND

PMID: 9241126 (View on PubMed)

Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE; Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001 Sep 1;98(5):1302-11. doi: 10.1182/blood.v98.5.1302.

Reference Type: BACKGROUND

PMID: 11520775 (View on PubMed)

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88.

Reference Type: BACKGROUND

PMID: 9058730 (View on PubMed)

Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood. 2003 Jun 1;101(11):4233-44. doi: 10.1182/blood-2002-08-2510. Epub 2003 Jan 9. No abstract available.

Reference Type: BACKGROUND

PMID: 12522002 (View on PubMed)

Hagglund H, Ringden O, Agren B, Wennberg L, Remberger M, Rundquist L, Svahn BM, Aspelin P. Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant. 1998 Feb;21(4):331-5. doi: 10.1038/sj.bmt.1701116.

Reference Type: BACKGROUND

PMID: 9509965 (View on PubMed)

Hansen JA and Dupont B. HLA 2004 Immunobiology of the Human MHC. Proceedings of the 13th IHWC. IHWG Press 2004, Seattle, WA (USA).

Reference Type: BACKGROUND

Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J, Rizzieri D, McPherson J, Chao N. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant. 2008 May;14(5):591-4. doi: 10.1016/j.bbmt.2008.02.016.

Reference Type: BACKGROUND

PMID: 18410902 (View on PubMed)

Josefson A. A new method of treatment - intraossal injections. Acta Med Scand 1934; 81:550-564.

Reference Type: BACKGROUND

Komatsu T, Narimatsu H, Yoshimi A, Kurita N, Kusakabe M, Hori A, Murashige N, Matsumura T, Kobayashi K, Yuji K, Tanaka Y, Kami M. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol. 2007 Jan;86(1):49-54. doi: 10.1007/s00277-006-0190-5. Epub 2006 Oct 12.

Reference Type: BACKGROUND

PMID: 17036221 (View on PubMed)

Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996 Jul 18;335(3):157-66. doi: 10.1056/NEJM199607183350303.

Reference Type: BACKGROUND

PMID: 8657213 (View on PubMed)

Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001 Jun 14;344(24):1815-22. doi: 10.1056/NEJM200106143442402.

Reference Type: BACKGROUND

PMID: 11407342 (View on PubMed)

List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297.

Reference Type: BACKGROUND

PMID: 15561689 (View on PubMed)

Locatelli F, Giorgiani G, Giraldi E, Castelnovi C, Stroppa P, Bernardo ME, Bonetti F, Maccario R. Cord blood transplantation in childhood. Haematologica. 2000 Nov;85(11 Suppl):26-9. No abstract available.

Reference Type: BACKGROUND

PMID: 11268320 (View on PubMed)

Long GD, Laughlin M, Madan B, Kurtzberg J, Gasparetto C, Morris A, Rizzieri D, Smith C, Vredenburgh J, Halperin EC, Broadwater G, Niedzwiecki D, Chao NJ. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2003 Dec;9(12):772-80. doi: 10.1016/j.bbmt.2003.08.007.

Reference Type: BACKGROUND

PMID: 14677117 (View on PubMed)

Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872.

Reference Type: BACKGROUND

PMID: 9508168 (View on PubMed)

Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med. 2003 Jul;9(7):959-63. doi: 10.1038/nm886.

Reference Type: BACKGROUND

PMID: 12796774 (View on PubMed)

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903. doi: 10.1056/NEJM199410063311402.

Reference Type: BACKGROUND

PMID: 8078551 (View on PubMed)

Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000 Oct 15;96(8):2717-22.

Reference Type: BACKGROUND

PMID: 11023503 (View on PubMed)

Moretta A, Maccario R, Fagioli F, Giraldi E, Busca A, Montagna D, Miniero R, Comoli P, Giorgiani G, Zecca M, Pagani S, Locatelli F. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 2001 Mar;29(3):371-9. doi: 10.1016/s0301-472x(00)00667-6.

Reference Type: BACKGROUND

PMID: 11274766 (View on PubMed)

Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, Yamane A, Ikeda Y, Okamoto S. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Transplant Proc. 2007 Jun;39(5):1615-9. doi: 10.1016/j.transproceed.2006.12.042.

Reference Type: BACKGROUND

PMID: 17580201 (View on PubMed)

Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T, Masuoka K, Kusumi E, Kishi Y, Matsumura T, Wake A, Morinaga S, Kanda Y, Taniguchi S. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol. 2006 Jan;132(1):36-41. doi: 10.1111/j.1365-2141.2005.05832.x.

Reference Type: BACKGROUND

PMID: 16371018 (View on PubMed)

Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H, Hamaguchi M, Watanabe M, Kohno A, Murata M, Sawa M, Miyamura K, Morishita Y. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant. 2007 Jan;39(1):31-9. doi: 10.1038/sj.bmt.1705539. Epub 2006 Nov 20.

Reference Type: BACKGROUND

PMID: 17115066 (View on PubMed)

Narimatsu H, Watanabe M, Kohno A, Sugimoto K, Kuwatsuka Y, Uchida T, Murata M, Miyamura K, Morishita Y; Nagoya Blood and Marrow Transplantation Group (NBMTG). High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan. Bone Marrow Transplant. 2008 Apr;41(8):753-6. doi: 10.1038/sj.bmt.1705978. Epub 2008 Jan 14. No abstract available.

Reference Type: BACKGROUND

PMID: 18195683 (View on PubMed)

Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, Ishii K, Ohno N, Nagamura F, Uchimaru K, Tojo A, Asano S. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood. 2004 Jan 15;103(2):489-91. doi: 10.1182/blood-2003-07-2420. Epub 2003 Aug 21.

Reference Type: BACKGROUND

PMID: 12933570 (View on PubMed)

Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K, Shimohakamada Y, Ohno N, Uchimaru K, Nagamura F, Tojo A, Asano S. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood. 2003 Jun 15;101(12):4711-3. doi: 10.1182/blood-2002-12-3917. Epub 2003 Feb 13.

Reference Type: BACKGROUND

PMID: 12586621 (View on PubMed)

Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, Remberger M, Michel G, Arcese W, Dallorso S, Tiedemann K, Busca A, Chan KW, Kato S, Ortega J, Vowels M, Zander A, Souillet G, Oakill A, Woolfrey A, Pay AL, Green A, Garnier F, Ionescu I, Wernet P, Sirchia G, Rubinstein P, Chevret S, Gluckman E. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001 May 15;97(10):2962-71. doi: 10.1182/blood.v97.10.2962.

Reference Type: BACKGROUND

PMID: 11342418 (View on PubMed)

Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008 Jan;41(2):207-14. doi: 10.1038/sj.bmt.1705963. Epub 2007 Dec 17.

Reference Type: BACKGROUND

PMID: 18084331 (View on PubMed)

Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000 Jun 22;342(25):1846-54. doi: 10.1056/NEJM200006223422501.

Reference Type: BACKGROUND

PMID: 10861319 (View on PubMed)

Rubinstein P, Carrier C, Carpenter C et al. Graft selection in unrelated placental/umbilical cord blood (PCB) transplantation: influence and weight of HLA match and cell dose on engraftment and survival [abstract]. Blood 2000; 96:588a.

Reference Type: BACKGROUND

Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol. 2000 Dec;13(4):565-84. doi: 10.1053/beha.2000.0106.

Reference Type: BACKGROUND

PMID: 11102277 (View on PubMed)

Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, Garnier F, Douek D, Gluckman E, Charron D, Toubert A. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood. 2002 Feb 15;99(4):1458-64. doi: 10.1182/blood.v99.4.1458.

Reference Type: BACKGROUND

PMID: 11830500 (View on PubMed)

Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, Matsumura T, Seo S, Matsuno N, Masuoka K, Kusumi E, Yuji K, Miyakoshi S, Matsuzaki M, Yoneyama A, Taniguchi S. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant. 2008 May;14(5):583-90. doi: 10.1016/j.bbmt.2008.03.003.

Reference Type: BACKGROUND

PMID: 18410901 (View on PubMed)

van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood. 1999 Nov 1;94(9):3055-61.

Reference Type: BACKGROUND

PMID: 10556189 (View on PubMed)

Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002 Sep 1;100(5):1611-8. doi: 10.1182/blood-2002-01-0294.

Reference Type: BACKGROUND

PMID: 12176879 (View on PubMed)

Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP, Hoang-Ngoc L, Maloisel F, Guerci A, Rochant H, Gratecos N, Casassus P, Janvier M, Brice P, Lepelley P, Fenaux P. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia. 1999 Apr;13(4):524-9. doi: 10.1038/sj.leu.2401387.

Reference Type: BACKGROUND

PMID: 10214857 (View on PubMed)

Yahata T, Ando K, Sato T, Miyatake H, Nakamura Y, Muguruma Y, Kato S, Hotta T. A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. Blood. 2003 Apr 15;101(8):2905-13. doi: 10.1182/blood-2002-07-1995. Epub 2002 Oct 31.

Reference Type: BACKGROUND

PMID: 12411299 (View on PubMed)

Bonifazi F, Dan E, Labopin M, Sessa M, Guadagnuolo V, Ferioli M, Rizzi S, De Carolis S, Sinigaglia B, Motta MR, Bontadini A, Giudice V, Martinelli G, Arpinati M, Cavo M, Bonafe M, Storci G. Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. Bone Marrow Transplant. 2019 May;54(5):717-725. doi: 10.1038/s41409-018-0335-x. Epub 2018 Sep 19.

Reference Type: DERIVED

PMID: 30232415 (View on PubMed)

Related Links

http://www.ebmt.org/

The European Group for Blood and Marrow Transplantation

http://www.gitmo.net/

Italian Group for Bone Marrow Transplantation and Cellular Therapy

Other Identifiers

152/2008/U/Sper

Identifier Type: -

Identifier Source: org_study_id